Citations

Clear

4847 citation(s) found for "Tu, Eric".

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI
Grant, Caroline W. , Ingraham, Brenden , Lennon, Ryan J. , Raina, Anvi , Tian, Shulan , Kowlgi, Gurukripa N. , Cavallari, Larisa H. , Lee, Craig R. , Beitelshees, Amber L. , Angiolillo, Dominick J. , Rossi, J. , Stouffer, George A. , Klee, Eric W. , Gulati, Rajiv, Rihal, Charanjit S. , Farkouh, Michael E. , Athreya, Arjun , Pereira, Naveen L. , Beitelshees, Amber L. , Ingraham, Brenden S , Kowlgi, Narayan G , Franchi, Francesco , Duarte, Julio D , Rossi, Joseph S , Stouffer, George A , Klee, Eric W , Rihal, Charanjit S. , Farkouh, Michael E , Athreya, Arjun P , Pereira, Naveen L , Angiolillo, Dominick J , Cavallari, Larisa H , Tian, Shulan , Lennon, Ryan J. , Duarte, Julio D. , Gulati, Rajiv , Athreya, Arjun P.

Mayo Clinic

Clinical and Translational Science | July 10, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1111/cts.70655 | PMID 42427167 Get It

ABSTRACT Ischemic events after contemporary percutaneous coronary intervention (PCI) are uncommon but carry high morbidity/mortality. Identifying patients at highest risk is critical to guide dual antiplatelet therapy (DAPT) intensity while minimizing bleeding. Current machine learning (ML) model‐developed risk scores do not incorporate pharmacogenetic data. To develop and externally validate ML models that integrate clinical, demographic, and CYP2C19 genetic information to predict 1‐year ischemic outcomes post‐PCI to refine clinical decision making. We analyzed 8317 patients from TAILOR‐PCI trial ( n = 4572) and the Precision PCI registry ( n = 3745). The outcome was a composite of cardiovascular death, myocardial infarction, stroke, and stent thrombosis at 1 year. Boruta feature selection identified 11 predictors. Multiple ML algorithms were trained in TAILOR‐PCI and validated in Precision PCI using cross‐validation and synthetic minority oversampling (SMOTE). Model performance was assessed by area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The best external performance was achieved with a support vector machine (SVM, polynomial kernel) (AUC 0.667; sensitivity 0.871; specificity 0.282), while XGBoost provided a more balanced profile (AUC 0.619; sensitivity 0.442; specificity 0.688). Variable importance for the SVM polynomial model demonstrated that all 11 included Boruta feature selected predictors had relatively high importance (> 75). ML models trained on large clinical trial and real‐world registry datasets can help identify the small subset of patients at high ischemic risk after PCI. This distinction is of relevance because ischemic events are rare, and most patients may safely de‐escalate DAPT to reduce bleeding risk while maintaining ischemic protection through a multimodal approach to risk stratification. Trial Registration: TAILOR‐PCI URL: https://clinicaltrials.gov/ct2/show/NCT01742117
Early Versus Late Recurrence in Olfactory Neuroblastoma: A Multi‐Institutional Analysis of Predictive Risk Factors
Harris, Alexandria , Tang, Anthony, Fung, Nicholas , Champagne, Pierre‐Olivier, Fernandez-Miranda, Juan, Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis, Patel, Zara M. , Patel, Zara M., Celda, María Peris, Pinheiro-Neto, Carlos D., Sanusi, Olabisi, Thorp, Brian D., Gompel, Jamie J. Van, Zenonos, Georgios, Zwagerman, Nathan T., Bell, Diana, Kuan, Edward C., Geltzeiler, Mathew, Hwang, Peter H , Patel, Zara , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Tang, Anthony , Almeida, João Paulo , Champagne, Pierre‐Olivier , Kalyvas, Aristotelis , Pinheiro‐Neto, Carlos , Sanusi, Olabisi , Thorp, Brian D. , Gompel, Jamie J. Van , Zenonos, Georgios A. , Zwagerman, Nathan T. , Bell, Diana , Kuan, Edward C , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/alr.70216 | PMID 42422976 Get It

ABSTRACT Background Olfactory neuroblastoma (ONB) exhibits variable recurrence patterns, with significant late recurrences occurring years after treatment. We investigated cutoff periods to define late recurrence and identified predictors that distinguish patients at risk of late recurrence from those considered cured. Methods From a multi‐institutional cohort of 219 ONB patients treated at nine centers, we analyzed 77 patients with documented recurrence. Using a 48‐month cutoff to define early (< 48 months) versus late (≥ 48 months) recurrence, we evaluated 35 clinical, anatomic, and treatment variables using Firth penalized logistic regression across three comparisons: (1) late versus early recurrence timing, (2) late recurrence versus no recurrence, and (3) early recurrence versus no recurrence. Results Thirty‐four of the 77 (44.2%) recurrences were classified as late. Among the 77 patients who recurred, smaller tumor volume (OR 0.243, p = 0.035) and lower novel Dulguerov staging (OR 0.802, p = 0.038) were associated with late, rather than early recurrence. When patients with late recurrence were compared to those who remained disease‐free, radiographic skull base bone involvement was the strongest independent predictor (OR 2.90, 95% CI 1.14–8.64, p = 0.025), and this effect strengthened after adjusting for tumor volume (OR 3.80, p = 0.029). Pathologic dural invasion (OR 3.29, p = 0.013), Kadish stage (OR 2.02, p = 0.026), and T‐stage (OR 1.32, p = 0.040) were also significant. Conclusions A 48‐month cutoff effectively stratifies ONB recurrence risk. Skull base bone involvement independently predicts recurrence when compared to nonrecurrent cases and uniquely persists as a risk factor for late recurrence. These findings establish skull base bone involvement as a novel biomarker for risk‐stratified surveillance protocols.
Real‐time motion tracking of a gold implant in water by Cherenkov lights
Okazaki, Keita , Brost, Eric, Natanasabapathi, Gopishankar , Watanabe, Yoichi , Brost, Eric, Natanasabapathi, Gopishankar

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 8, 2026 | Volume: 27 | Issue: 7 | Pages: No page available

10.1002/acm2.70684 | PMID 42415277 Get It

Abstract Background The intra‐fraction motion of tumors during radiation therapy can be monitored using imaging systems based on X‐ray imaging (e.g., kV/MV radiography or CBCT) or magnetic resonance imaging (MRI). However, these techniques have limitations, including additional ionizing radiation dose and the need for complex, expensive equipment. Hence, a non‐invasive, lower‐cost motion‐tracking approach that does not add radiation would be beneficial for routine clinical applications. Purpose To study the feasibility of tracking the dynamic motion of a small gold marker in water by using Cherenkov photons produced by MV photon beams, through Monte Carlo simulations and experiments. Methods The GAMOS Monte Carlo code, which includes an optical simulation module, was used to calculate the deposited dose and Cherenkov‐light yield in a water phantom. Phase‐space files for 6, 10, 15, and 10 MV flattening filter‐free (FFF) beams served as photon sources. The simulation setup consisted of a 20 × 20 × 20 cm 3 water phantom with an 8 × 12 × 0.25 mm 3 gold planar implant at its center. Percent depth dose (PDD) and Cherenkov‐light yield were evaluated throughout the phantom and near the gold implant. For experimental validation, a 20 × 20 × 20 cm 3 glass water tank was placed on a programmable platform executing sinusoidal, sawtooth, and sharkfin motions (± 20 mm amplitude; 10‐ and 60‐s cycles). A 5 × 5 cm 2 10 MV FFF beam (2400 MU/min) irradiated the gold implant. A scientific CMOS camera (f/2.0) positioned at 80 cm from the implant captured Cherenkov images. Repeatability was quantified by the standard deviation (SD) across motion cycles. The accuracy was assessed as the absolute difference between the bright‐room reference position and the Cherenkov‐derived position. Images of the implant in sinusoidal motion were also acquired during delivery of a two‐arc brain volumetric modulated arc therapy (VMAT) plan (Arc A and Arc B). Results Monte Carlo simulations showed that Cherenkov light yield throughout the phantom closely correlated with the PDD for all beam energies. The Cherenkov light yield upstream of the gold implant increased by 6.12%, 7.16%, 9.11%, and 7.01% compared to the Cherenkov light yield without the gold implant for 6, 10 FFF, 10, and 15 MV beams, respectively. Experiments confirmed that the beam‐facing side of the gold implant appeared brighter than the opposite side, indicating enhanced backscattered electron production. Cherenkov‐based positional measurements of the periodically moving implant showed close agreement with bright‐room references. For static beams, accuracy across motion patterns was < 0.70 mm with repeatability < 0.2 mm. For the VMAT plan, the accuracies were < 0.50 mm (Arc A) and < 0.70 mm (Arc B). Conclusion The Cherenkov‐light yield was strongly correlated with the deposited dose and showed a notable enhancement around the gold implant. Cherenkov light imaging successfully tracked the dynamic motion of a gold implant in water under high‐dose rate conditions, demonstrating its potential for real‐time fiducial tracking in radiation therapy without additional radiation exposure.
High natural variation of BvCR4 homologs in sea beet contrasts with narrow genetic base of sugar beet: Implications for Cercospora leaf spot resistance
Martinez, Ana, Wyatt, Samuel, Neubauer, Jonathan, Reeves, Pat, Richards, Chris, Branch, Eric , Bolton, Melvin, Wyatt, Nathan, Neubauer, Jonathan D., Reeves, Pat, Richards, Christopher M. , Chu, Chenggen , Bolton, Melvin, Wyatt, Nathan A.

Mayo Clinic

Plant Disease | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1094/pdis-01-26-0161-re | PMID 42410683 Get It

Cercospora leaf spot (CLS) is a destructive disease of sugar beet (Beta vulgaris ssp. vulgaris L.) for which resistance conferred by the gene BvCR4 has been introgressed from sea beet (B. vulgaris ssp. maritima). BvCR4-mediated resistance has been broadly deployed to manage CLS globally in sugar beet; however, continuous implementation exerts strong selection pressure, increasing the risk of disease outbreaks due to resistance-breaking C. beticola populations. This study aimed to identify BvCR4 variants in public B. vulgaris spp. germplasm to assess their genetic and structural diversity. Polymerase chain reaction screening of 589 public B. vulgaris spp. germplasm detected BvCR4 homologs in 32 accessions with diverse responses to CLS including historically relevant sugar beet lines represented in breeding programs and Mediterranean sea beet populations of diverse genetic backgrounds. Analysis of the genomic sequences revealed higher diversity in sea beet compared to sugar beet. Additionally, population genetic analysis indicated that BvCR4 homologs in sugar beet likely originated from sea beet populations in Italy and Greece. We identified historical cultivated materials carrying full proteins encoded by BvCR4 alleles and delineated geographic regions where sea beet populations harbor BvCR4 homologs that may be useful in breeding programs. Structural variation was largely circumscribed within leucine-rich repeat domains, although CLS resistance phenotyping was not associated with specific polymorphisms, suggesting BvCR4-mediated resistance may rely on interactions with other co-receptors. This study provides resources for sugar beet improvement by enabling the identification of BvCR4 homologs in diverse germplasm and disclosing materials with potentially novel resistance.
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1 -ALS Autopsy Tissue Donors
Sellon, Monica Thanawala, Roemer, Shanu F., Monine, Michael, Harris, Nicole , Bartlett, Dan, David, Eric, Xu, Shanqin, Jandreski, Luke , Malek, Sohail, Garafalo, Steve, Nestorov, Ivan , Ireland, Margaret D., Bowser, Robert , Korobeynikov, Vladislav, Ravits, John, Shaw, Pamela J., Highley, J. Robin, Ferguson, Toby A. , Fradette, Stephanie , Graham, Danielle , Sorenson, Eric J. , Oskarsson, Björn, Reichard, R. Ross , Dickson, DW, Paganoni, Sabrina, Oakley, Derek H., Frosch, Matthew P. , Miller, Timothy M. , Bucelli, Robert C., Perrin, Richard J., Plowey, Edward D., Guise, Amanda J. , Roemer, Shanu F. , Monine, Michael I. , Comfort, Nicole T. , Nestorov, Ivan, King, Andrew, Korben, Vlad A. , Ravits, John , Shaw, Pamela J. , Highley, J. Robin , Dickson, Dennis W. , Paganoni, Sabrina , Babu, Suma , Oakley, Derek H. , Bucelli, Robert C. , Perrin, Richard J. , Ly, Cindy V. , Plowey, Edward D.

Mayo Clinic

JAMA Neurology | July 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2195 | PMID 42406382 Get It

Importance Tofersen is a disease-modifying antisense oligonucleotide therapeutic for people living with SOD1 –amyotrophic lateral sclerosis ( SOD1 -ALS). Autopsy tissue donors have provided the first opportunity to study the distribution of intrathecally administered tofersen in human central nervous system tissues. Objectives To determine the tissue distribution of tofersen and to provide the first estimates of SOD1 reduction in human somatic motor systems tissues. Design, Setting, and Participants This was a cross-sectional autopsy tissue case series conducted between 2018 and 2026. Autopsies were performed at 3 US academic medical institutions. Tissue samples from 8 deceased patients who lived with SOD1 -ALS, participated in tofersen clinical trials (ClinicalTrials.gov Identifiers NCT02623699 [An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)] and NCT03070119 [Long-Term Evaluation of BIIB067 (Tofersen)]) or the Expanded Access Program, and whose families authorized autopsies were eligible for this study. All autopsy tissue donors known at the time of this study were included (none were excluded). Analyses were conducted between August 2020 and January 2026. Exposures Participants received multiple intrathecal 20- to 100-mg tofersen doses. Main Outcomes and Measures Tofersen tissue concentrations were measured using hybridization enzyme-linked immunosorbent assay (ELISA). SOD1 messenger RNA (mRNA) and protein reduction estimates, defined as percentage SOD1 levels in this study’s recently treated autopsy tissue donors compared to a cohort of samples from tofersen-naive SOD1 -ALS autopsy tissue donors, were measured using quantitative reverse transcription polymerase chain reaction (PCR) and ELISA. Histological localization of tofersen and SOD1 transcripts were studied using immunohistochemistry and in situ hybridization assays. Results In 8 tofersen-treated autopsy tissue donors (5 male and 3 female donors; age range, 42-66 years), spinal cord and motor cortical tissue tofersen concentrations strongly correlated with predictions based on individual dosing histories and a preclinical pharmacokinetic model. For 3 recently treated autopsy tissue donors, reductions in lumbar spinal cord tissue SOD1 mRNA and protein levels ranged from 45% to 84% despite not having been administered 1 to 2 scheduled doses before autopsy. Residual somatic motor neurons demonstrated tofersen transduction and low SOD1 mRNA probe hybridization. Misfolded SOD1 protein inclusions were detected in residual motor neurons of tofersen-naive SOD1- ALS tissue donor controls and tofersen-treated tissue donors. Meningeal and perivascular lymphocytic immune responses were observed in 5 recently treated tissue donors but were not apparent in tissue donors with remote final tofersen doses. Conclusions and Relevance This case series presents the first emerging autopsy tissue data confirming the predicted distribution of tofersen and robust SOD1 protein reduction in human somatic motor systems tissues.
RF Noise Artifacts From a High Frequency Spinal Cord Stimulation System: A Retrospective Imaging Cohort With Illustrative Cases
Stinson, Eric G. , Hubbard, Abby, Kleinow, Jenna E. , Kramer, Emily A., Trzasko, Joshua D. , Shu, Yunhong , Edmonson, Heidi A. , Hubbard, Abby J, Hubbard, Abby J.

Mayo Clinic

Journal of Magnetic Resonance Imaging | July 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jmri.70394 | PMID 42402451 Get It

ABSTRACT Unexpected RF noise artifact “followed” a patient with an implanted spinal cord stimulator to multiple MR systems. Subsequent testing and clinical scanning showed no artifact, implying that the artifact originated from the implanted device. MR exams ( n = 173) performed over a two‐year period in patients ( n = 122) who had implanted spinal cord stimulators from the same manufacturer were reviewed for artifacts and device models. RF noise artifacts were observed in ~50% of exams in patients with a specific model of spinal cord stimulator, but only ~1%–8% of exams in other models from the same manufacturer. We hope that by describing this artifact, health care professionals can avoid service costs and scheduling delays.
Comparing those Most Satisfied Versus Least Satisfied Following Surgery for Cervical Spondylotic Myelopathy
Chan, Andrew K., Park, Christine , Shaffrey, Christopher I., Gottfried, Oren N., Than, Khoi D., Ef, Bisson, Williamson, Theresa , Bydon, Mohamad, Asher, Anthony L. , Coric, Domagoj , Potts, Eric A., Foley, Kevin T., Wang, Michael Y., Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott, Park, Paul, Upadhyaya, Cheerag, Yen, Chun-Po, Uribe, Juan S., Tumialán, Luis M., Turner, Jay, Chou, Dean, Haid, Regis W., Mummaneni, Praveen V., Chan, Andrew K. , Shaffrey, Christopher I. , Than, Khoi D. , Bisson, Erica F. , Bydon, Mohamad , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Meyer, Scott, Yen, Chun-Po , Uribe, Juan S. , Tumialán, Luis M. , Turner, Jay D. , Chou, Dean , Mummaneni, Praveen V.

Mayo Clinic

Spine | July 3, 2026 | Volume: 51 | Issue: 15 | Pages: 1093-1100

10.1097/brs.0000000000005402 | PMID 42398026 Get It

Study Design. Post hoc analysis of prospectively-collected data. Objective. To identify factors predicting the most (and least) satisfaction following surgery for cervical spondylotic myelopathy (CSM). Summary of Background Data. Patient satisfaction affects long-term outcomes after surgery but the preoperative factors that influence postoperative satisfaction have not been well studied in patients with CSM. Methods. We conducted a post hoc analysis of prospectively-collected data from the Quality Outcomes Database (QOD) CSM registry cohort. Baseline and surgical characteristics were compared for patients with CSM reporting the most [North American Spine Society Satisfaction Score (NASS) 1] and least (NASS 4) satisfaction 24 months postoperatively. A multivariable logistic regression model was constructed using backward stepwise elimination to determine significant predictors of most versus least satisfaction. Twenty-four-month patient-reported outcomes (PROs) were compared. Results. Overall, 1141 patients were prospectively enrolled with 948 (83.1%) reaching 24-month follow-up. Of these, 699 met prespecified inclusion criteria: 610 (87.3%) were most satisfied and 89 (12.7%) were least satisfied. Though there were mean improvements in all 24-month PROs for the most satisfied cohort ( P <0.001), there were no significant improvements in 24-month PROs for the least satisfied cohort ( P >0.05). Using multivariable logistic regression modeling, a preoperative symptom of upper extremity weakness (OR=2.5, P =0.003), subjective myelopathy (OR=2.0, P =0.04), absence of numbness complaints (OR=2.2, P =0.003), symptom duration under 12 months (OR=1.6, P =0.047), Caucasian race (OR=2.3, P =0.001), participation in activities outside of the home (OR=2.0, P =0.04), anterior approach (OR=2.3, P <0.001), and higher baseline quality of life (OR=4.0, P =0.01) were predictive of the most satisfaction. Conclusion. Compared with the least satisfied, those most satisfied following surgery for CSM more often had a preoperative symptom of arm weakness, subjective myelopathy, the absence of numbness complaints, symptom duration under 12 months, higher baseline quality of life, and participation in activities outside of the home. Compared with a posterior approach, an anterior approach was associated with the most satisfaction. Taken together, early surgical treatment--before myelopathic symptoms significantly impact one's quality of life--may be considered to optimize patient satisfaction following CSM surgery.
First-in-Human Safety and Feasibility of Nodal and Pedal MR Lymphangiography with Gadopiclenol
Thompson, Scott M. , Collins, Jeremy D. , Bendel, Emily C. , Reisenauer, Christopher J., Jundt, Michael C., Yalҫin, Müge, Favazza, Christopher , Lu, Aiming , McDonald, Robert J. , Williamson, Eric E. , Stinson, Eric G. , In, MyungHo, Favazza, Christopher P , Messina, Steven A , Collins, Jeremy , Williamson, Eric , Thompson, Scott , Bendel, Emily , In, Myung-Ho , Jundt, Michael C., In, Myung‐Ho , Messina, Steven A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | July 2, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1148/ryct.260067 | PMID 42390347 Get It

Dynamic gadopiclenol-enhanced nodal and pedal MR lymphangiography was safe, with no adverse events, and feasible for imaging peripheral and central conducting lymphatic anatomy.
Association of a Polygenic Risk Score with Diagnosis and Outcomes in Idiopathic Pulmonary Fibrosis
Kalra, S. , Grilli, Christopher, Coombes, Brandon J. , Armasu, Sebastian M. , Upjohn, D, Egan, Jan B. , Chen, Qingwen , Tern, Courtney , Zhang, Chengyue, Rose, Jonathan A. , Putman, Rachel, McDermott, Greg, Hsieh, Yuli Lily , Bublitz, Michele L., Carmona, Eva M. , Klee, Eric W, Lazaridis, K, Peljto, Anna L. , Schwartz, D A, Silverman, Edwin K. , Olson, Janet, Walker, T, Zamora, Ana C., Zein, Joe , Ortega, V E, Cohort, Tapestry, McDermott, Gregory C , Kalra, Sean S , Grilli, Christopher B , Armasu, Sebastian , Upjohn, David P , Hsieh, Yuli L , Lasky-Su, Jessica , Silverman, Edwin K , Allen, Richard J , Walker, T'Nita, Wain, Louise V , Zamora, Ana, Zein, Joe G, Hunninghake, Gary M , Moll, Matthew , Cho, Michael H , Carmona, Eva M , McDermott, Gregory , Coombes, Brandon J , Putman, Rachel K. , Kn, Lazaridis, Lasky‐Su, Jessica , Dudbridge, Frank , Allen, Richard J. , Olson, JA, Hunninghake, Gary M. , Ali, Ahmad Hafiz , Sekulić, Aleksandar , Athreya, Arjun P. , Clermont, Blake J, N, Brittany, Burnap, Graddy, Courtney B., Cahn, Elliot, Klee, Eric W. , Sicotte, Hugues , Ekpoh, Idara U., Frank, Jacob A., Bruflat, Jamie K., Kemppainen, Jennifer L., Samadder, Jewel, Presutti, John J, Leitzke, Jon W, Lazaridis, Konstantinos N. , Tree, Kristine M, Jones, Leila A, Bandel, Lorelei A. , Karow, Mary E., Peterson, Melanie M., Bublitz, Michelle L. , Morales-Rosado, Joel, Erwin, Nate P., Larson, Nicholas B. , Olson, Rory, Vierkant, Robert A., Pignolo, Robert J. , Safgren, Stephanie, Bagaria, Sanjay P. , Tian, Shulan , Kaggal, Suneetha, Walker, T'Nita S., Wilson, Tammy A., McAllister, Tammy M., Tan-Arroyo, Jennifer, Luehrs, Tony, Ortega, Victor E. , Chen, Wenan , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag271 | PMID 42391602 Get It

Abstract Rationale Idiopathic Pulmonary Fibrosis (IPF) is characterized by chronic progressive pulmonary fibrosis and high mortality. Genetic markers, summarized into a polygenic risk score (PRS), associate with IPF in well-phenotyped research cohorts. Objectives To evaluate the performance of the PRS using real-world data from routinely captured electronic healthcare records. Methods We conducted an observational study evaluating the association of a PRS for IPF with electronic healthcare record diagnosis of IPF as well as lung transplant-free survival in four independent cohorts; the Mass General Brigham Biobank (MGBB), Mayo Clinic Biobank (MCBB), Mayo Clinic Tapestry Cohort (Tapestry), and U.K. Biobank (UKBB). We used multivariable logistic regression and multivariable Cox proportional hazards models adjusting for age, gender, and principal components of ancestry. The cohorts then underwent fixed and random effects meta-analysis. Measurements and Main Results Of 37,709; 44,195; 43,202; and 447,422 participants from MGBB, MCBB, Tapestry and UKBB respectively, 1,015 (2.7%) 2,879 (6.5%), 1,310 (3.0%), and 2,742 (0.6%) participants had an IPF diagnosis. Meta-analysis demonstrated a high-risk PRS associated with IPF diagnosis, OR 2.88 (95%CI 2.41-3.44) compared to all other individuals. A high-risk PRS also associated with the composite endpoint of mortality or lung transplant among those with an IPF diagnosis, HR 1.23(95%CI 1.11-1.35) compared to all other individuals. Conclusions A PRS can identify those at risk for an IPF diagnosis and mortality in biobank-scale data, which may have implications for clinical decisions. Further work is necessary to evaluate the utility of adding genetics in clinical settings.
A Second Report of a Missense Variant in AMMECR1 Causing Midface Hypoplasia, Hearing Impairment, Elliptocytosis, and Nephrocalcinosis: Case Report and Lit
Tan, Jia W., Wilke, Matheus Vernet Machado Bressan , Panwar, Deepak , Kahn, Eva S., Figueiral, Marta , Xiao, Yao , Sas, David J. , Lanpher, Brendan C. , Vairo, Filippo Pinto e, Klee, Eric W. , Pinto E Vairo, Filippo, Wilke, Matheus V M B , Panwar, Deepak , Dikilitas, Ozan

Mayo Clinic

Clinical Genetics | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/cge.70209 | PMID 42386221 Get It

ABSTRACT Pathogenic variants in AMMECR1 have been associated with a rare multisystem disorder characterized by midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis (MFHIEN). To date, most reported cases involve copy number variants or presumed loss‐of‐function alterations, with only a single prior report describing a missense variant supported by functional studies. Here, we report a patient with a heterozygous de novo AMMECR1 missense variant, NM_015365.3:c.649G>A p.(Val217Met) presenting with clinical features consistent with MFHIEN, including midface hypoplasia, partial hearing impairment, nephrocalcinosis, and elliptocytosis identified on peripheral blood smear. Comparative review of the literature highlights that while previously reported missense variants in AMMECR1 demonstrated altered intranuclear protein distribution and reduced expression in functional assays, clinical evidence supporting pathogenicity of non‐truncating variants remains limited. The phenotypic overlap between our patient and prior report strengthens the association between missense variations and the MFHIEN phenotype. Our findings support the pathogenic relevance of missense variation in AMMECR1 and emphasize the importance of integrating detailed phenotyping, including hematologic evaluation, with genomic data in the diagnosis of rare multisystem disorders. Additional cases and functional studies are needed to clarify genotype–phenotype correlations and underlying disease mechanisms.